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Background: The antioxidant melatonin effectively scavenges highly toxic hydroxyl radicals. Decreases in
circulating melatonin levels have been reported in patients with diseases that become more serious with advancing
age. The purpose of the present study was to explore the relationship between circulatory melatonin level and the
extent of senile cataracts. To this end, we assessed the urinary excretion levels of 6-sulphatoxymelatonin (aMTS6),
a major metabolite of melatonin.
Methods: A total of 22 patients (aged 64 ± 7 years; 12 males and 10 females) with senile cataracts and 22 healthy
controls (aged 61 ± 8 years, 12 males and 10 females) were studied. aMTS6 urine levels were measured using
commercial ELISA kits. Each aMTS6 level was expressed as [aMTS6] (in ng)/[mg] creatinine. As the data were not
normally distributed, the Mann–Whitney U-test was employed to assess the statistical validity of the difference
observed.
Results: The aMT6 level in nocturnal urine was 17.87 ± 14.43 ng aMTS6/mg creatinine (mean ± SD) in senile
cataract patients; this was 76% of the level measured in age- and gender-matched controls (23.28 ± 16.27 ng
aMTS6/mg creatinine). This difference in nocturnal urine aMTS6 level between senile cataract patients and controls
was not statistically significant (p = 0.358).
Conclusion: The urinary aMTS6 level did not differ between subjects with and without senile cataracts.
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As is true of many other tissues, the normal human eye
undergoes several structural changes with advancing age
[1]. Most of the described anatomic and physiological
changes are associated with gradual functional declines,
such that the quality of vision deteriorates over time.
Degenerative eye changes that progress more rapidly in
some aging subjects than in others are associated with
development of a variety of age-related ocular diseases
including senile cataract formation and age-related
macular degeneration (AMD) [2,3]; these conditions are
the major causes of blindness worldwide [4].
The pathophysiologies of age-related ocular diseases
are complex and remain poorly understood. Oxidative
stress, associated with cellular damage caused by reactive* Correspondence: yaseminbudak2000@yahoo.com
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reproduction in any medium, provided the oroxygen intermediates (ROIs), has been implicated in the
development of both AMD [5-8] and cataracts [5,9].
ROIs, which include free radicals, hydrogen peroxide,
and singlet oxygen, are primarily generated as toxic
byproducts of various cellular O2-consuming processes
[10,11]. The retina is particularly susceptible to oxidative
stress because this tissue is characterized by high oxygen
consumption, has a high proportion of polyunsaturated
fatty acids, and is regularly exposed to bright light [11].
Together, these factors create a chronic oxidative burden
that can damage retinal proteins, DNA, and lipids [11].
Under normal conditions, the antioxidant defense sys-
tems of the body can easily neutralize free radicals pro-
duced by toxic reactions. However, although the extent
of oxidative stress increases with age, the ability of cells
to detoxify reactive oxygen intermediates deteriorates as
subjects age. Together, deterioration of the capacity to
detoxify such materials, and the cumulative effects of
oxidative stress, have been proposed to constitute a localal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dered to be a major cause of cataract formation [12-14].
Melatonin (N-acetyl-5-methoxy-tryptamine), the prin-
cipal secretory product of the pineal gland, is a most ef-
fective antioxidant that scavenges highly toxic hydroxyl
radicals [15-19]. Endogenous melatonin production falls
dramatically with age [20], and decreases in circulating
melatonin levels have been reported in patients with
age-related ocular diseases [21].
The purpose of the present study was to explore a
possible relationship between circulatory melatonin levels
and development of senile cataracts via assessment of
6-sulphatoxymelatonin (aMT6) excretion in first-morning
urine samples, which is an accurate indicator of peak
plasma melatonin concentrations during the previous
night [22].
Methods
The present case–control prospective study involved
non-institutionalized subjects aged 60 years or more. All
experiments were carried out in accordance with the
tenets of the Declaration of Helsinki (1989) of the
World Medical Association. Our study was approved by
the Bursa Regional Ethics Committee and all subjects
provided written informed consent.
All subjects in the case and control groups were exa-
mined by an expert ophthalmologist. Routine ophthalmic
examinations including determination of visual acuity,
slit lamp examination, ophthalmoscopy, and intraocular
pressure measurement, were performed. A cataract was
diagnosed when lens opacity was advanced to an extent
that impaired vision. Controls were cataract-free subjects
who were individually matched with cases on age and sex.
Inclusion criteria were the presence any type of senile
cataract (posterior subcapsular, cortical, nuclear or mixed
type) from grade I to III in an otherwise normal eye in
patients older than 60 years. Any patient with secondary
cataracts was excluded. Thus, those with cataracts caused
by trauma, diabetes, and other known causes, did not
participate in the study.
Subjects with a history of current or previous liver or
kidney disease were excluded, as were shift workers,
those with sleep disorders, those who had just experi-
enced a long-distance flight, and those who had taken
melatonin orally within the prior 2 weeks.
The aMTS6 levels in nocturnal urine specimens were
determined in duplicate using a commercial competitive
enzyme-linked immunosorbent assay (ELISA) kit from
DRG Instruments GmbH (Marburg, Germany). Fifty mi-
croliters of 1:51 dilutions of urine samples were added
to 50 μl of a solution of a melatonin sulfate peroxidase-
conjugate, and then 50 μl of an anti-melatonin rabbit
antibody solution was added. After incubation for 2 h at
room temperature in an orbital shaker (500 rpm), allsamples were washed four times with 250 μl of phos-
phate buffer and were next mixed with 100 μl of a
tetramethylbenzidine/hydrogen peroxide solution (1:31,
v/v). These mixtures were incubated for a further
30 min at room temperature on an orbital shaker. One
hundred μl of 1 M sulfuric acid was subsequently added
as the stopping solution. Absorption levels at 450 nm
were measured within 1 h and the amount of aMTS6 in
each urine specimen was calculated following the manu-
facturer’s instructions. The interassay coefficients of vari-
ation were 8.2% and 5.8% when 10 control samples with
14.5–62 aMTS ng/ml were assayed on two occasions.
All aMTS6 levels were standardized to those of creati-
nine to control for differences caused by variations in urine
dilution. Urine creatinine levels were assayed using a com-
mercial automated clinical chemistry system (Dimension
RxL; Siemens Healthcare Diagnostics Inc., Newark, DE).
In each instance, the urine aMTS6 level was divided by
the urine creatinine concentration to obtain a normalized
value for the urine aMTS6 level, expressed as ng aMTS6/mg
creatinine.
Statistical analysis
All statistical tests were conducted with the aid of SPSS
for Windows version 13.0 (SPSS Inc., Chicago, IL). Data
are presented either as percentages or as means ± SDs.
The Mann–Whitney U test was used, when appropriate,
to assess the significance of observed differences be-
tween the two groups. A p value of ≤0.05 was considered
to be significant.
Results
Twenty-two senile cataract patients (aged 64 ± 7 years; 12
males and 10 females), and 22 normal subjects (aged 61 ±
8 years; 12 males and 10 females), were studied (Table 1).
The aMTS6 level in nocturnal urine was 17.87 ± 14.43 ng/
mg creatinine (mean ± SD) in senile cataract patients; this
was 77% of the value observed in age- and gender-
matched controls (23.28 ± 16.27 ng/mg creatinine (min:
8.52-max:58.10 ng/mg creatinine)) (Figure 1). This diffe-
rence was not statistically significant (p = 0.358).
Discussion
We explored whether melatonin levels differed between
patients with age-related cataracts and normal subjects
by measuring the levels of aMTS6, a major metabolite of
melatonin. The urinary excretion level of aMTS6 has
been previously shown to be a reliable surrogate of the
blood melatonin level, reflecting nocturnal synthesis of
melatonin by the pineal gland [23]. High correlations
between 24-h plasma and serum melatonin levels, on
the one hand, and urinary melatonin levels, on the
other, have been reported previously [24-27].
Table 1 Demographical and laboratory data of senile
cataract patients and controls
Senile cataract Control
Age 64 ± 7 61 ± 8
Gender (male/female) 12/10 12/10
aMTS6 (ng/mg creatinine) 17.87 ± 14.43 (3.48-54.61)* 23.28 ± 16.27
(8.52-58.10)*
*Numbers in parentheses indicate minimum and maximum values.
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poorly understood, many studies have suggested that ge-
netic factors and oxidative stress are both of major impor-
tance in the development of the condition [28]. Hundreds
of publications have described the free-radical- scavenging
and antioxidant actions of melatonin [29]. Melatonin
levels in patients with AMD have been suggested to be
lower than in aged subjects without AMD, because the
former patients show greater decreases in nocturnal urine
aMTS6 levels than do the latter. Thus, AMD may be asso-
ciated with a greater decrease in melatonin levels than is
characteristic of those who age normally, and a melatonin
deficiency may influence development of AMD [30].
The melatonin levels of senile cataract patients have
not been previously reported. To the best of our know-
ledge, the present study is the first to compare urinary
aMTS6 levels in senile cataract patients with those in
age-matched controls. Our initial hypothesis was that se-
nile cataract patients would have lower aMTS6 levels
than did normal subjects. Although the level of urinary








Figure 1 Urinary ng MTS6/mg creatinine levels in patients with
senile cataract (P), and matched control subjects (C). The center
lines represent the median values.age-matched controls, the difference was not statistically
significant.
We found no relationship between urinary aMTS6
levels and development of senile cataracts. It is widely
accepted that melatonin production by the pineal gland
declines progressively with age [31]. Therefore, in elderly
subjects, the melatonin level is much less than that of
young individuals [32]. Melatonin is produced in the
pineal gland but also in many other tissues and organs;
such extrapineal production is much greater than that of
the pineal gland [33-35]. However, even the most active
peripheral sources of melatonin (including the retina)
appear to contribute to only a limited extent to systemic
hormone levels; the level of local catabolism appears to
be high. Melatonin can be produced by ocular cells,
pinealocytes, retinal photoreceptors, and ciliary epithelial
cells [36-38], all of which operate under the direct con-
trol of a circadian clock [39]. Indeed, previous studies
have shown that retinal melatonin may possibly act as a
free-radical scavenger within photoreceptors [40,41].
Local production of melatonin may cause the melatonin
concentration surrounding photoreceptors to be rela-
tively high, protecting such cells from oxidative insult ei-
ther via exertion of a direct antioxidant activity or via
activation of melatonin receptors. The level of melatonin
produced in the eye is far less than that produced in the
pineal body [36,37,41]. It is widely accepted that blood
melatonin is derived exclusively from the pineal gland in
mammals [4,36,38]. Therefore, the circulating melatonin
level is only one of several factors determining mela-
tonin levels in the eye. Because any association between
the melatonin levels of the blood and the lens is poorly
understood, it remains unclear whether existing bio-
chemical data (largely derived from measurements
performed on blood) accurately reflect lens melatonin
levels. Therefore, we cannot conclude that ocular mela-
tonin levels differed between our senile cataract patients
and the control group.
The limitations of the present study are that the num-
ber of cases was limited, possibly compromising the sta-
tistical power of the study; and also that the standard
deviations in mean urinary melatonin concentrations
were large.
Conclusion
We found that the urinary aMTS6 level did not appear
to differ between those with and without senile cata-
racts. Our findings do not support the hypothesis that
age-related reductions in the efficacy of antioxidant
defense systems trigger biochemical cascades causing
age-related cataract formation. However, future studies
including larger sample sizes are warranted to confirm
the validity of this observation, as well as to reveal the
exact role of melatonin in senile cataract formation.
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